Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

exenatide

BYDUREON

exenatide (BYDUREON) is a glucagon-like peptide 1 receptor agonist.

EMA: approved NMPA: clinical trials Alimentary tract and metabolism (A10) A10BJ01
Patents linked 6
Pipeline programs 11
News articles 0
Drug details — exenatide
Class
Alimentary tract and metabolism (A10)
Route
—
Patents
6
Programs
11
Data quality
0.83
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

exenatide (BYDUREON) is a glucagon-like peptide 1 receptor agonist.

Key facts

INN exenatide
Brand BYDUREON
Mechanism Glucagon-like peptide 1 receptor agonist
Target Glucagon-like peptide 1 receptor
Therapeutic class Alimentary tract and metabolism (A10)
ATC code A10BJ01

Mechanism of action

Glucagon-like peptide 1 receptor agonist

Primary target: Glucagon-like peptide 1 receptor

Approval history

Authority Status Date
EMA approved —
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. exenatide once weekly Phase 3 · AstraZeneca · Type 2 Diabetes Mellitus
  2. Byetta 10 micrograms solution for injection in pre-filled pen Phase 2 · George Institute for · Hypopituarism
  3. EXENATIDE Phase 2 · Disc Medicine · paragangliomas
  4. EXENATIDE Phase 2 · Disc Medicine · Gestational diabetes
  5. EXENATIDE , VERAPAMIL Phase 2 · Disc Medicine · type 1 diabetes mellitus
  6. GEN-100 Phase 2 · Anaxis Pharma · Acute Ischemic Stroke
  7. Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） Phase 1 · First People's Hospital · T2DM
  8. Exenatide Approved · First People's Hospital · Type 2 Diabetes

Related & competitor drugs

Browse all drugs
  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Related patents

Browse patents

  1. US 11179467

    Exenatide modifier and use thereof

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11026998

    Shaped mass composition comprising exenatide

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10350162

    Methods and compositions for oral administration of exenatide

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10029080

    Method for delivering exenatide into a lumen of the intestinal tract using a swallowable drug delivery device

    Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9511121

    Method for delivering exenatide to a patient in need thereof

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8969293

    Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is exenatide?

exenatide (BYDUREON) is a glucagon-like peptide 1 receptor agonist.

What is the brand name for exenatide?

BYDUREON is a marketed brand name for exenatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.